These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 603318)

  • 41. Pharmacodynamics of the initiation of antiarrhythmic therapy with lorcainide.
    Winkle RA; Keefe DL; Rodriguez I; Kates RE
    Am J Cardiol; 1984 Feb; 53(4):544-51. PubMed ID: 6198895
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Anti-arrhythmic effect of tocainide (lidocaine congener) on ventricular arrhythmias (author's transl)].
    Kuck KH; Hanrath P; Lubda J; Mathey D; Bleifeld W
    Dtsch Med Wochenschr; 1979 Nov; 104(48):1701-5. PubMed ID: 93043
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effects of oral and injectable flecainide in patients with an accessory atrioventricular pathway].
    Fauchier JP; Cosnay P; Rouesnel P; Moquet B; Bonnet P; Scala PJ; Demeyer JF
    Arch Mal Coeur Vaiss; 1985 Oct; 78 Spec No():81-90. PubMed ID: 3938264
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravenous lorcainide for symptomatic ventricular tachyarrhythmias: comparison with lidocaine and oral lorcainide.
    Hohnloser SH; Podrid PJ; Lown B
    Am Heart J; 1988 Apr; 115(4):824-30. PubMed ID: 3354411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of intravenous lorcainide with lidocaine for acute therapy of complex ventricular arrhythmias: results of a randomized study with crossover option.
    Anderson JL; Anastasiou-Nana M; Lutz JR; Writer SL
    J Am Coll Cardiol; 1985 Feb; 5(2 Pt 1):333-41. PubMed ID: 3881497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of lorcainide, a new antiarrhythmic drug, in patients with cardiac rhythm disorders.
    Somani P
    Am J Cardiol; 1981 Jul; 48(1):157-63. PubMed ID: 7246437
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initial and long-term outpatient experience with lorcainide for suppression of malignant and potentially malignant ventricular arrhythmias.
    Anastasiou-Nana MI; Anderson JL; Hampton EM; Nanas JN; Lutz JR
    Am Heart J; 1985 Dec; 110(6):1168-75. PubMed ID: 4072873
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Flecainide: a new agent for the treatment of ventricular arrhythmias.
    Grubb BP; Tilley-Gray B
    Am J Med Sci; 1986 Sep; 292(3):160-3. PubMed ID: 3529958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lorcainide (R 15 889), a first review.
    Amery WK; Heykants JJ; Xhonneux R; Towse G; Oettel P; Gough DA; Janssen PA
    Acta Cardiol; 1981; 36(3):207-34. PubMed ID: 7020313
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lorcainide. A comparative trial with quinidine gluconate in patients with previously untreated ventricular arrhythmias.
    Falk RH; O'Brien JL
    Chest; 1984 Oct; 86(4):537-40. PubMed ID: 6383741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long term lorcainide therapy guided by electrophysiology studies.
    Somberg J; Butler B; Flowers D; Tepper D; Torres V
    Acta Cardiol; 1985; 40(6):621-36. PubMed ID: 3879419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and tolerance of intravenous flecainide in patients with chronic high frequency ventricular arrhythmias.
    Stroobandt R; Andries E; van Mieghem W; Kesteloot H
    Eur Heart J; 1984 Nov; 5(11):876-82. PubMed ID: 6397356
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lorcainide treatment of Wolff-Parkinson-White syndrome in children and adolescents.
    Samánek M; Hrobonová V; Bartáková H
    Pediatr Cardiol; 1987; 8(1):3-9. PubMed ID: 2440013
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravenous and oral lorcainide: assessment of central nervous system toxicity and antiarrhythmic efficacy.
    Vlay SC; Mallis GI
    Am Heart J; 1986 Mar; 111(3):452-5. PubMed ID: 3953352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.
    Somani P; Temesy-Armos PN; Leighton RF; Goodenday LS; Fraker TD
    Am Heart J; 1984 Dec; 108(6):1443-8. PubMed ID: 6507240
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lorcainide for high-frequency ventricular arrhythmia: preliminary results of a short-term double-blind and placebo-controlled crossover study and long-term follow-up.
    Singh SN; DiBianco R; Kostroff LI; Fletcher RD; Cockrell JL
    Am J Cardiol; 1984 Aug; 54(4):22B-28B. PubMed ID: 6380261
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preliminary study of pirmenol in the treatment of ventricular arrhythmias.
    Gimeno Gascon JV; Algarra Vidal FJ
    Am J Cardiol; 1987 Jun; 59(16):53H. PubMed ID: 3591713
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pirmenol in the long-term treatment of chronic ventricular arrhythmias: a placebo-controlled study.
    Toivonen LK; Nieminen MS; Manninen V; Frick MH
    J Cardiovasc Pharmacol; 1986; 8(1):156-60. PubMed ID: 2419679
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of malignant ventricular arrhythmia--experience with lorcainide.
    Podrid PJ; Lown B
    Am J Cardiol; 1984 Aug; 54(4):29B-36B. PubMed ID: 6465044
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and electrophysiologic effects of chronic lorcainide therapy in refractory ventricular tachycardia.
    Saksena S; Rothbart ST; Cappello G; Bernstein A; Somani P
    J Am Coll Cardiol; 1983 Sep; 2(3):538-44. PubMed ID: 6875117
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.